In contrast, AFP testing is mature, cost-effective, and widely available, but it often fails to detect early-stage HCC and can produce false positives, especially in patients with chronic liver disease (104–106) (Table 3). The gene discussed is AFP; the disease is hepatocellular carcinoma.